For: | Fujimori N, Umemura T, Kimura T, Tanaka N, Sugiura A, Yamazaki T, Joshita S, Komatsu M, Usami Y, Sano K, Igarashi K, Matsumoto A, Tanaka E. Serum autotaxin levels are correlated with hepatic fibrosis and ballooning in patients with non-alcoholic fatty liver disease. World J Gastroenterol 2018; 24(11): 1239-1249 [PMID: 29568204 DOI: 10.3748/wjg.v24.i11.1239] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v24/i11/1239.htm |
Number | Citing Articles |
1 |
Yumi Tsuchida, Hirofumi Shoda, Tetsuji Sawada, Keishi Fujio. Role of autotaxin in systemic lupus erythematosus. Frontiers in Medicine 2023; 10 doi: 10.3389/fmed.2023.1166343
|
2 |
Ashley Vander Does, Cynthia Levy, Gil Yosipovitch. Cholestatic Itch: Our Current Understanding of Pathophysiology and Treatments. American Journal of Clinical Dermatology 2022; 23(5): 647 doi: 10.1007/s40257-022-00710-2
|
3 |
Alexandros Arjmand, Constantinos T. Angelis, Vasileios Christou, Alexandros T. Tzallas, Markos G. Tsipouras, Evripidis Glavas, Roberta Forlano, Pinelopi Manousou, Nikolaos Giannakeas. Training of Deep Convolutional Neural Networks to Identify Critical Liver Alterations in Histopathology Image Samples. Applied Sciences 2019; 10(1): 42 doi: 10.3390/app10010042
|
4 |
Leen J. M. Heyens, Dana Busschots, Ger H. Koek, Geert Robaeys, Sven Francque. Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment. Frontiers in Medicine 2021; 8 doi: 10.3389/fmed.2021.615978
|
5 |
Richell Booijink, Fernando Salgado‐Polo, Craig Jamieson, Anastassis Perrakis, Ruchi Bansal.
A type
IV
Autotaxin inhibitor ameliorates acute liver injury and nonalcoholic steatohepatitis
. EMBO Molecular Medicine 2022; 14(9) doi: 10.15252/emmm.202216333
|
6 |
Yasushi Honda, Kento Imajo, Takashi Kobayashi, Takaomi Kessoku, Yuji Ogawa, Wataru Tomeno, Masato Yoneda, Noritoshi Kobayashi, Satoru Saito, Atsushi Nakajima. Autotaxin is a valuable biomarker for the prediction of liver fibrosis in patients with non‐alcoholic fatty liver disease. Hepatology Research 2019; 49(10): 1136 doi: 10.1111/hepr.13382
|
7 |
Shereen Abou Bakr Saleh, Khaled Mohamed Abdelwahab, Asmaa Mady Mady, Ghada Abdelrahman Mohamed. The impact of achieving a sustained virological response with direct-acting antivirals on serum autotaxin levels in chronic hepatitis C patients. Egyptian Liver Journal 2020; 10(1) doi: 10.1186/s43066-020-00060-w
|
8 |
Lenche Kostadinova, Carey L Shive, Donald D Anthony. Elevated Autotaxin and LPA Levels during Chronic Viral Hepatitis and Hepatocellular Carcinoma Associate with Systemic Immune Activation. Cancers 2019; 11(12): 1867 doi: 10.3390/cancers11121867
|
9 |
Takanobu Iwadare, Takefumi Kimura, Taiki Okumura, Shun-ichi Wakabayashi, Taro Nakajima, Shohei Kondo, Hiroyuki Kobayashi, Yuki Yamashita, Ayumi Sugiura, Naoyuki Fujimori, Tomoo Yamazaki, Hideo Kunimoto, Satoshi Shimamoto, Koji Igarashi, Satoru Joshita, Naoki Tanaka, Takeji Umemura. Serum autotaxin is a prognostic indicator of liver-related events in patients with non-alcoholic fatty liver disease. Communications Medicine 2024; 4(1) doi: 10.1038/s43856-024-00499-7
|
10 |
Caiyun Nie, Lei Zhang, Xiaobing Chen, Ying Li, Fushuang Ha, Hua Liu, Tao Han. Autotaxin: An Early Warning Biomarker for Acute-on-chronic Liver Failure. Journal of Clinical and Translational Hepatology 2020; 8(3): 1 doi: 10.14218/JCTH.2020.00045
|
11 |
Ayda Esmaeili, Soha Namazi. Is melatonin effective for pruritus caused by liver disease?. Medical Hypotheses 2018; 121: 177 doi: 10.1016/j.mehy.2018.10.004
|
12 |
Jacqueline A.G.M. Langedijk, Dagmar Tolenaars, Ruth Bolier, Yi-Té Lee, Amber Meurs, Catherine Williamson, Luciano Adorini, Stan F.J. van de Graaf, Ulrich Beuers, Ronald Oude Elferink. Inhibition of autotaxin by bile salts and bile salt-like molecules increases its expression by feedback regulation. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2021; 1867(11): 166239 doi: 10.1016/j.bbadis.2021.166239
|
13 |
Abhishek Gairola, Aaron Wetten, Jessica Dyson. Sodium/bile acid co-transporter inhibitors currently in preclinical or early clinical development for the treatment of primary biliary cholangitis. Expert Opinion on Investigational Drugs 2024; 33(5): 485 doi: 10.1080/13543784.2024.2343789
|
14 |
Leke Wiering, Pallavi Subramanian, Linda Hammerich. Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease. Cellular and Molecular Gastroenterology and Hepatology 2023; 15(6): 1277 doi: 10.1016/j.jcmgh.2023.02.010
|
15 |
Yoshio Sumida, Masashi Yoneda, Katsutoshi Tokushige, Miwa Kawanaka, Hideki Fujii, Masato Yoneda, Kento Imajo, Hirokazu Takahashi, Yuichiro Eguchi, Masafumi Ono, Yuichi Nozaki, Hideyuki Hyogo, Masahiro Koseki, Yuichi Yoshida, Takumi Kawaguchi, Yoshihiro Kamada, Takeshi Okanoue, Atsushi Nakajima. FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic. Life 2021; 11(2): 143 doi: 10.3390/life11020143
|
16 |
Charalambos Papadopoulos, Konstantinos Mimidis, Dimitris Papazoglou, George Kolios, Ioannis Tentes, Konstantinos Anagnostopoulos. Red Blood Cell-Conditioned Media from Non-Alcoholic Fatty Liver Disease Patients Contain Increased MCP1 and Induce TNF-α Release. Reports of Biochemistry and Molecular Biology 2022; 11(1): 54 doi: 10.52547/rbmb.11.1.54
|
17 |
Naoyuki Fujimori, Takefumi Kimura, Naoki Tanaka, Tomoo Yamazaki, Taiki Okumura, Hiroyuki Kobayashi, Shun‐ichi Wakabayashi, Yuki Yamashita, Ayumi Sugiura, Jonathan Pham, Sai P. Pydi, Kenji Sano, Satoru Joshita, Takeji Umemura. 2‐Step PLT16‐AST44 method: Simplified liver fibrosis detection system in patients with non‐alcoholic fatty liver disease. Hepatology Research 2022; 52(4): 352 doi: 10.1111/hepr.13745
|
18 |
Hideki Fujii, Norifumi Kawada. The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease. International Journal of Molecular Sciences 2020; 21(11): 3863 doi: 10.3390/ijms21113863
|
19 |
Ali Sepehrinezhad, Ali Shahbazi, Mohammad Taghi Joghataei, Fin Stolze Larsen, Sajad Sahab Negah. Inhibition of autotaxin alleviates pathological features of hepatic encephalopathy at the level of gut–liver–brain axis: an experimental and bioinformatic study. Cell Death & Disease 2023; 14(8) doi: 10.1038/s41419-023-06022-5
|
20 |
Yoshifumi Morita, Makoto Kurano, Eriko Morita, Satoshi Shimamoto, Koji Igarashi, Motoji Sawabe, Junken Aoki, Yutaka Yatomi. Urinary autotaxin concentrations are associated with kidney injury. Clinica Chimica Acta 2020; 509: 156 doi: 10.1016/j.cca.2020.06.019
|
21 |
Hatsue Fujino, Mio Tanaka, Michio Imamura, Kei Morio, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Tomokazu Kawaoka, Shoichi Takahashi, Daiki Miki, Masataka Tsuge, Akira Hiramatsu, Hiroshi Aikata, C. Nelson Hayes, Kazuaki Chayama. Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis. BMC Gastroenterology 2019; 19(1) doi: 10.1186/s12876-019-1092-z
|
22 |
Jacqueline A. G. M. Langedijk, Ulrich H. Beuers, Ronald P. J. Oude Elferink. Cholestasis-Associated Pruritus and Its Pruritogens. Frontiers in Medicine 2021; 8 doi: 10.3389/fmed.2021.639674
|
23 |
Takanobu Iwadare, Takefumi Kimura, Naoki Tanaka, Tomoo Yamazaki, Shun-ichi Wakabayashi, Taiki Okumura, Hiroyuki Kobayashi, Yuki Yamashita, Sai P. Pydi, Tomoyuki Nakajima, Mai Iwaya, Ayumi Sugiura, Satoru Joshita, Takeshi Uehara, Takeji Umemura. Circulating thrombospondin 2 levels reflect fibrosis severity and disease activity in HCV-infected patients. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-23357-9
|
24 |
Ashish Verma, Ishan Kumar, Manish Indal, Sunit Shukla, Pramod Kumar Singh, Ram Chandra Shukla. Variation in hepatic segmental portal venous pulsed wave Doppler flow distribution in patients with NAFLD: A pilot study. Ultrasound 2023; 31(4): 300 doi: 10.1177/1742271X231154862
|
25 |
Alexandros Arjmand, Constantinos T. Angelis, Alexandros T. Tzallas, Markos G. Tsipouras, Evripidis Glavas, Roberta Forlano, Pinelopi Manousou, Nikolaos Giannakeas. Deep Learning in Liver Biopsies using Convolutional Neural Networks. 2019 42nd International Conference on Telecommunications and Signal Processing (TSP) 2019; : 496 doi: 10.1109/TSP.2019.8768837
|
26 |
Anouk Gijbels, Sophie Schutte, Diederik Esser, Suzan Wopereis, Gerard Bryan Gonzales, Lydia A. Afman. Effects of a 12-week whole-grain or refined wheat intervention on plasma acylcarnitines, bile acids and signaling lipids, and association with liver fat: A post-hoc metabolomics study of a randomized controlled trial. Frontiers in Nutrition 2022; 9 doi: 10.3389/fnut.2022.1026213
|
27 |
Nancy Abdel Fattah Ahmed, Ahmed Galal Deiab, Ahmad Shawki Mohammad Hasan, Ahmad Mohamed Yousry Abd Elbaky. Serum autotaxin levels in responders to HCV treatment by direct-acting antivirals. Egyptian Liver Journal 2020; 10(1) doi: 10.1186/s43066-020-00051-x
|
28 |
Lijuan Zhao, Yan Duan, Zhaoxing Li, Juan Li, Shunxiang Li. Unearthing the Potential Therapeutic Effects of Oxyresveratrol Based on Intrinsic Links between Pharmacological Effects: Implications for the Gut–Liver–Brain Axis. Pharmaceuticals 2024; 17(8): 1063 doi: 10.3390/ph17081063
|
29 |
Takefumi Kimura, Naoki Tanaka, Naoyuki Fujimori, Tomoo Yamazaki, Takahito Katsuyama, Yuichi Iwashita, Jonathan Pham, Satoru Joshita, Sai P. Pydi, Takeji Umemura. Serum thrombospondin 2 is a novel predictor for the severity in the patients with NAFLD. Liver International 2021; 41(3): 505 doi: 10.1111/liv.14776
|
30 |
Michiharu Komatsu, Naoki Tanaka, Takefumi Kimura, Naoyuki Fujimori, Kenji Sano, Akira Horiuchi, Ayumi Sugiura, Tomoo Yamazaki, Soichiro Shibata, Satoru Joshita, Takeji Umemura, Akihiro Matsumoto, Eiji Tanaka. Miglitol attenuates non‐alcoholic steatohepatitis in diabetic patients. Hepatology Research 2018; 48(13): 1092 doi: 10.1111/hepr.13223
|
31 |
Su Jin Kim, Cody Howe, Jonathon Mitchell, Jieun Choo, Alexandra Powers, Angelos Oikonomopoulos, Charalabos Pothoulakis, Daniel W Hommes, Eunok Im, Sang Hoon Rhee. Autotaxin loss accelerates intestinal inflammation by suppressing TLR4‐mediated immune responses. EMBO reports 2020; 21(10) doi: 10.15252/embr.201949332
|
32 |
Yuichi Hiyama, Hatsue Fujino, Maiko Namba, Yasutoshi Fujii, Shinsuke Uchikawa, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Tomokazu Kawaoka, Daiki Miki, Masataka Tsuge, Shiro Oka. Value of autotaxin for hepatocellular carcinoma risk assessment in chronic hepatitis B patients treated with nucleos(t)ide analogs. Hepatology Research 2024; 54(11): 981 doi: 10.1111/hepr.14042
|
33 |
Ayami Fukiage, Hatsue Fujino, Daiki Miki, Yasutaka Ishii, Masahiro Serikawa, Masataka Tsuge, Michio Imamura, Hiroshi Aikata, C. Nelson Hayes, Kazuaki Chayama. Clinical Usefulness of Serum Autotaxin for Early Prediction of Relapse in Male Patients with Type 1 Autoimmune Pancreatitis. Digestive Diseases and Sciences 2021; 66(4): 1268 doi: 10.1007/s10620-020-06338-8
|
34 |
Kazuya Takemura, Etsuko Takizawa, Akihiro Tamori, Mika Nakamae, Hiroshi Kubota, Sawako Uchida-Kobayashi, Masaru Enomoto, Norifumi Kawada, Masayuki Hino. Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C. International Journal of Molecular Sciences 2020; 21(12): 4517 doi: 10.3390/ijms21124517
|
35 |
Kazuya Takemura, Etsuko Takizawa, Akihiro Tamori, Mika Nakamae, Hiroshi Kubota, Sawako Uchida‐Kobayashi, Masaru Enomoto, Norifumi Kawada, Masayuki Hino. Association of serum autotaxin levels with liver fibrosis in patients pretreatment and posttreatment with chronic hepatitis C. Journal of Gastroenterology and Hepatology 2021; 36(1): 217 doi: 10.1111/jgh.15114
|
36 |
Yoshihiro Kamada, Takahiro Nakamura, Satoko Isobe, Kumiko Hosono, Yukiko Suama, Yukie Ohtakaki, Arihito Nauchi, Naoto Yasuda, Soh Mitsuta, Kouichi Miura, Takuma Yamamoto, Tatsunori Hosono, Akihiro Yoshida, Ippei Kawanishi, Hideaki Fukushima, Masao Kinoshita, Atsushi Umeda, Yuichi Kinoshita, Kana Fukami, Toshio Miyawaki, Hideki Fujii, Yuichi Yoshida, Miwa Kawanaka, Hideyuki Hyogo, Asahiro Morishita, Hideki Hayashi, Hiroshi Tobita, Kengo Tomita, Tadashi Ikegami, Hirokazu Takahashi, Masato Yoneda, Dae Won Jun, Yoshio Sumida, Takeshi Okanoue, Atsushi Nakajima. SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: an expert review by the JANIT Forum. Journal of Gastroenterology 2023; 58(2): 79 doi: 10.1007/s00535-022-01932-1
|
37 |
Asahiro Morishita, Kyoko Oura, Kei Takuma, Mai Nakahara, Tomoko Tadokoro, Koji Fujita, Joji Tani, Tingting Shi, Takashi Himoto, Miwa Tatsuta, Akio Moriya, Tomonori Senoo, Akemi Tsutsui, Takuya Nagano, Koichi Takaguchi, Masafumi Ono, Tsutomu Masaki. Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study. Hepatology International 2023; 17(3): 606 doi: 10.1007/s12072-022-10453-1
|
38 |
Shanthi Makka, Shivarla Naveen, Shyam Sai Kamal Puranam, Shekapuram Srikesh. Artificial Intelligence in Biomedical and Modern Healthcare Informatics. 2025; : 339 doi: 10.1016/B978-0-443-21870-5.00032-7
|
39 |
Naoki Tanaka, Takefumi Kimura, Naoyuki Fujimori, Tadanobu Nagaya, Michiharu Komatsu, Eiji Tanaka. Current status, problems, and perspectives of non-alcoholic fatty liver disease research. World Journal of Gastroenterology 2019; 25(2): 163-177 doi: 10.3748/wjg.v25.i2.163
|